Contribution of Auger/conversion electrons to renal side effects after radionuclide therapy: preclinical comparison of 161Tb-folate and 177Lu-folate-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Contribution of Auger/conversion electrons to renal side effects after radionuclide therapy: preclinical comparison of 161Tb-folate and 177Lu-folate

Published:2016-02-09 Issue:1 Volume:6 Page:
ISSN:2191-219X
Container-title:EJNMMI Research
language:en
Short-container-title:EJNMMI Res

Author:

Haller Stephanie,Pellegrini Giovanni,Vermeulen Christiaan,van der Meulen Nicholas P.,Köster Ulli,Bernhardt Peter,Schibli Roger,Müller Cristina

Funder

Krebsliga Schweiz

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung

Swedish national cancer society

Publisher

Springer Science and Business Media LLC

Subject

Radiology Nuclear Medicine and imaging

Link

http://link.springer.com/content/pdf/10.1186/s13550-016-0171-1.pdf

Reference34 articles.

1. Lehenberger S, Barkhausen C, Cohrs S, Fischer E, Grünberg J, Hohn A, et al. The low-energy β- and electron emitter 161Tb as an alternative to 177Lu for targeted radionuclide therapy. Nucl Med Biol. 2011;38(6):917–24. doi: 10.1016/j.nucmedbio.2011.02.007 .

2. Müller C, Reber J, Haller S, Dorrer H, Bernhardt P, Zhernosekov K, et al. Direct in vitro and in vivo comparison of 161Tb and 177Lu using a tumour-targeting folate conjugate. Eur J Nucl Med Mol Imaging. 2014;41(3):476–85. doi: 10.1007/s00259-013-2563-z .

3. Nuclear National Data Center (Upton N.Y.) NuDat 2.6. http://www.nndc.bnl.gov/nudat2/ .

4. Eckerman K, Endo A. ICRP Publication 107. Nuclear decay data for dosimetric calculations. Ann ICRP. 2008;38(3):7–96. doi: 10.1016/j.icrp.2008.10.004 .

5. Kassis AI. Radiotargeting agents for cancer therapy. Expert Opin Drug Deliv. 2005;2(6):981–91. doi: 10.1517/17425247.2.6.981 .

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of polyethylene glycol-modified gold nanoparticles for the delivery of Lutetium-177- radiopharmaceuticals based on antibodies;Journal of Drug Delivery Science and Technology;2024-10

2. Developments in radionanotheranostic strategies for precision diagnosis and treatment of prostate cancer;EJNMMI Radiopharmacy and Chemistry;2024-08-24

3. Luminescent nanotherapeutics system for Real-Time imaging and Membrane-Mitochondria stepwise targeted drug delivery in ovarian cancer;Chemical Engineering Journal;2024-08

4. Comparison of the tolerability of 161Tb- and 177Lu-labeled somatostatin analogues in the preclinical setting;European Journal of Nuclear Medicine and Molecular Imaging;2024-07-24

5. Clinical Trial Protocol for VIOLET: A Single-Center, Phase I/II Trial Evaluation of Radioligand Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer with [¹⁶¹Tb]Tb-PSMA-I&T;Journal of Nuclear Medicine;2024-07-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3